Literature DB >> 12911851

Toxicity of antilipidemic agents: facts and fictions.

Antonios M Xydakis1, Peter H Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12911851     DOI： 10.1007/s11883-003-0012-3

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  54 in total

1.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

Review 2.  Statin-fibrate combination therapy.

Authors:  A Shek; M J Ferrill
Journal:  Ann Pharmacother       Date:  2001 Jul-Aug       Impact factor: 3.154

3.  Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.

Authors:  Thomayant Prueksaritanont; Raju Subramanian; Xiaojun Fang; Bennett Ma; Yue Qiu; Jiunn H Lin; Paul G Pearson; Thomas A Baillie
Journal:  Drug Metab Dispos       Date:  2002-05       Impact factor: 3.922

Review 4.  The benefits of niacin in atherosclerosis.

Authors:  S Tavintharan; M L Kashyap
Journal:  Curr Atheroscler Rep       Date:  2001-01       Impact factor: 5.113

5.  Mechanistic studies on metabolic interactions between gemfibrozil and statins.

Authors:  Thomayant Prueksaritanont; Jamie J Zhao; Bennett Ma; Brad A Roadcap; Cuyue Tang; Yue Qiu; Lida Liu; Jiunn H Lin; Paul G Pearson; Thomas A Baillie
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

6.  Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.

Authors:  Taha H Taher; Vladimir Dzavik; Ethel M Reteff; Glen J Pearson; Bonnie L Woloschuk; Gordon A Francis
Journal:  Am J Cardiol       Date:  2002-02-15       Impact factor: 2.778

7.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

Authors: 
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

8.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.

Authors:  D M Capuzzi; J R Guyton; J M Morgan; A C Goldberg; R A Kreisberg; O A Brusco; J Brody
Journal:  Am J Cardiol       Date:  1998-12-17       Impact factor: 2.778
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.